Literature DB >> 9612576

Research data on alendronate: biased opinions?

C Whiteside, B Lange.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9612576      PMCID： PMC2277664     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  5 in total

1.  Conflict of interest in the debate over calcium-channel antagonists.

Authors:  H T Stelfox; G Chua; K O'Rourke; A S Detsky
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

2.  Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.

Authors:  J D Adachi
Journal:  Can Fam Physician       Date:  1998-02       Impact factor: 3.275

3.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

4.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 5.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.